Clinical Trials Directory

Trials / Completed

CompletedNCT02600988

Immunomodulatory Effect of Vitamin D in Allogenic Post-transplant

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
150 (actual)
Sponsor
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether vitamin D is effective in the prevention of graft-versus-host-disease after completion of allogeneic transplant.

Detailed description

The allogeneic transplant of haematopoietic cell is the only treatment option for many malignant blood diseases. Unfortunately, the progression free survival and the quality of life of transplanted patients is limited due to the development of graft-versus-host-disease (GVHD). The development of new prophylaxis strategies of GVHD based in the use of immunomodulator agents (allowing the generation of an immunotolerance state and avoiding the use of immunosuppression) is essential. The GVHD is due to the cytotoxic effect of the donor lymphocytes T against healthy organs and tissues of the receptor. Calcineurin inhibitor combined with methotrexate or antibodies anti-lymphocytes T are used as standard prophylaxis. This type of antibodies has demonstrated efficacy to reduce GVHD, but have not increased survival due to increasing the risk of relapses and serious post-transplant infections. Due to its interactions with VDR (vitamin D receptor) present in immune system cells, vitamin D is able to inhibit the activation of dendritic cells and the proliferation and production of cytokines by lymphocytes T. Based on this effect, the peri- and post- transplant administration of vitamin D might decrease the risk of GVHD in allogeneic transplanted patients, subsequently decreasing the immunosuppressant treatment requirements and improving the prognosis of those patients.

Conditions

Interventions

TypeNameDescription
DRUG1000IU/day of Vitamine DAdministration of a specified dose of Vitamine D
DRUG5000IU/day of Vitamine DAdministration of a specified dose of Vitamine D

Timeline

Start date
2011-07-01
Primary completion
2015-04-01
Completion
2015-04-01
First posted
2015-11-10
Last updated
2015-11-10

Locations

7 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT02600988. Inclusion in this directory is not an endorsement.